UY37293A - Forma farmacéutica de unidades múltiples que comprende un núcleo con unidades centrales individuales cubiertas por un material muco-adhesivo, y un recubrimiento de núcleo entérico - Google Patents

Forma farmacéutica de unidades múltiples que comprende un núcleo con unidades centrales individuales cubiertas por un material muco-adhesivo, y un recubrimiento de núcleo entérico

Info

Publication number
UY37293A
UY37293A UY0001037293A UY37293A UY37293A UY 37293 A UY37293 A UY 37293A UY 0001037293 A UY0001037293 A UY 0001037293A UY 37293 A UY37293 A UY 37293A UY 37293 A UY37293 A UY 37293A
Authority
UY
Uruguay
Prior art keywords
core
muco
pharmaceutical form
adhesive material
understanding
Prior art date
Application number
UY0001037293A
Other languages
English (en)
Inventor
Jose Oliveira Varum Felipe
Carlos Bravo Gonzalez Roberto
Daniel Preisig
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of UY37293A publication Critical patent/UY37293A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una forma farmacéutica de unidades múltiples que comprende un núcleo, donde el núcleo comprende una pluralidad de unidades individuales, donde cada unidad comprende un principio farmacéuticamente activo y cada unidad está cubierta con un material muco-adhesivo, y donde la forma farmacéutica de unidades múltiples comprende, además, una capa de recubrimiento del núcleo. La invención se refiere, además, al uso de dicha forma farmacéutica de unidades múltiples en el tratamiento de trastornos inflamatorios, en especial para el tracto gastrointestinal.
UY0001037293A 2016-06-14 2017-06-14 Forma farmacéutica de unidades múltiples que comprende un núcleo con unidades centrales individuales cubiertas por un material muco-adhesivo, y un recubrimiento de núcleo entérico UY37293A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16174466.9A EP3257501A1 (en) 2016-06-14 2016-06-14 Multiple unit dosage form comprising a core with individual core units covered by a mucoadhesive material, and an enteric core coating

Publications (1)

Publication Number Publication Date
UY37293A true UY37293A (es) 2018-01-02

Family

ID=56131433

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037293A UY37293A (es) 2016-06-14 2017-06-14 Forma farmacéutica de unidades múltiples que comprende un núcleo con unidades centrales individuales cubiertas por un material muco-adhesivo, y un recubrimiento de núcleo entérico

Country Status (9)

Country Link
US (1) US20190336449A1 (es)
EP (2) EP3257501A1 (es)
JP (1) JP2019518758A (es)
AR (1) AR108729A1 (es)
CA (1) CA3026840A1 (es)
MA (1) MA45240A (es)
TW (1) TW201742621A (es)
UY (1) UY37293A (es)
WO (1) WO2017216088A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108434109A (zh) * 2018-04-25 2018-08-24 首都医科大学附属北京儿童医院 微型巯嘌呤片、微型巯嘌呤肠溶缓释片、及其制备方法
EP3613414A1 (de) 2018-08-24 2020-02-26 Dr. Falk Pharma Gmbh Pellets mit mehrschichtiger struktur zur verzögerten freisetzung des wirkstoffs im distalen kolon
CN112770730B (zh) * 2018-09-06 2024-02-13 瑞士西北应用科学与艺术大学 受控的药物释放制剂
KR102928844B1 (ko) * 2018-09-06 2026-02-19 파흐호흐슐레 노르트베스치바이츠 약물 방출 제어형 제형
ES3002632T3 (en) * 2018-12-07 2025-03-07 Tillotts Pharma Ag Delayed release drug formulation comprising an outerlayer with an enzymatically degradable polymer, its composition and its method of manufacturing
CA3216303A1 (en) * 2021-04-20 2022-10-27 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Capsule for specific drug delivery and preparation method therefor
AU2024241638A1 (en) * 2023-03-28 2025-10-09 Tillotts Pharma Ag Solid oral dosage form comprising antibodies for sustained release in the lower gastrointestinal tract

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA825384B (en) 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
US4627851A (en) 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
CA2634160C (en) * 2006-01-05 2014-04-15 Lifecycle Pharma A/S Disintegrating loadable tablets
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
CA2687130C (en) 2007-05-07 2017-10-03 Evonik Roehm Gmbh Solid dosage forms comprising an enteric coating with accelerated drug release
GB0808537D0 (en) * 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
EP2168572A1 (en) 2008-09-30 2010-03-31 Omya Development Ag New controlled release active agent carrier
EP2264108B1 (en) 2009-06-15 2012-02-15 Omya Development AG Process to prepare a surface-reacted calcium carbonate implementing a weak acid
PL2659881T3 (pl) 2012-04-30 2018-05-30 Tillotts Pharma Ag Formulacja leku o opóźnionym uwalnianiu
JP6273356B2 (ja) 2013-10-29 2018-01-31 ティロッツ・ファルマ・アクチエンゲゼルシャフトＴｉｌｌｏｔｔｓ Ｐｈａｒｍａ Ａｇ 遅延放出性薬物製剤

Also Published As

Publication number Publication date
AR108729A1 (es) 2018-09-19
EP3468538A1 (en) 2019-04-17
TW201742621A (zh) 2017-12-16
EP3257501A1 (en) 2017-12-20
US20190336449A1 (en) 2019-11-07
WO2017216088A1 (en) 2017-12-21
CA3026840A1 (en) 2017-12-21
JP2019518758A (ja) 2019-07-04
MA45240A (fr) 2019-04-17

Similar Documents

Publication Publication Date Title
UY37293A (es) Forma farmacéutica de unidades múltiples que comprende un núcleo con unidades centrales individuales cubiertas por un material muco-adhesivo, y un recubrimiento de núcleo entérico
ES2631980T3 (es) Formas de dosificación orales farmacéuticas que comprenden dabigatrán etexilato y sus sales farmacéuticamente aceptables
MX2015009104A (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
CL2019001714A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer.
NI202000099A (es) Compuestos de purinona y su uso en el tratamiento del cáncer
CO2017012362A2 (es) Formas de dosificación sólida que comprenden palbociclib, un ácido hidrosoluble y un portador farmacéuticamente aceptable y métodos para su produccion y uso
MX2021002322A (es) Nuevos metodos.
UY35586A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CO2017011437A2 (es) Composiciones de nanopartículas para terapia sostenida
MX366317B (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
BR112013024585A8 (pt) formas de dosagem farmacêutica de liberação controlada
CO7141411A2 (es) Formulaciones y métodos para la administración vaginal de antiprogestinas
MX2017013797A (es) Inhibidor de janus quinasa.
CL2016000143A1 (es) Comprimido farmacéutico que comprende ácido acetilsalicílico y clopidogrel
MX2018003497A (es) Formulaciones de aminoacidos de liberacion modificada administradas por via oral.
MX2015009045A (es) Composiciones y metodos para tratar el dolor severo.
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
CL2016003306A1 (es) Comprimidos probióticos bicapa de doble liberación
UY35344A (es) Oestra-1,3,5(10),16-tetraeno-3-carboxamidas
UY35693A (es) Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso
CY1118327T1 (el) Χρηση ενος παραγωγου πυραζολιου στην αντιμετωπιση οξεων εξαρσεων χρονιας αποφρακτικης πνευμονοπαθειας
CL2017000845A1 (es) Inhibidores de gingipaina de lisina
CR20150096A (es) Formulaciones de trans-clomifeno y usos de los mismas
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20230626